Stock Track | Palvella Therapeutics Soars 6.18% Intraday on Narrowed Loss and Positive Clinical Updates

Stock Track

Mar 31

Palvella Therapeutics' stock surged 6.18% during Tuesday's intraday trading session following the release of its full year 2025 financial results and a comprehensive corporate update.

The biopharmaceutical company reported a narrowed net loss of $3.71 per diluted share for 2025, an improvement from a loss of $7.83 per share in the prior year. This result also came in better than the $3.52 loss per share anticipated by analysts polled by FactSet.

Investor sentiment was further bolstered by several positive developments in the company's clinical pipeline. Palvella announced that the New Drug Application for its lead candidate, QTORIN™ rapamycin for microcystic lymphatic malformations, remains on track for submission in the second half of 2026. Additionally, the company plans to initiate a Phase 3 trial for cutaneous venous malformations in the latter half of 2026 and a Phase 2 trial for angiokeratomas in the second quarter of 2026. The corporate update also highlighted a recently completed $230 million equity financing that significantly strengthened the company's balance sheet.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1128000407"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128000407\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128000407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128000407","market":"us","top_or_hot":-1,"title":"Stock Track | Palvella Therapeutics Soars 6.18% Intraday on Narrowed Loss and Positive Clinical Updates","media":"Stock Track","content":"<p>Palvella Therapeutics' stock surged 6.18% during Tuesday's intraday trading session following the release of its full year 2025 financial results and a comprehensive corporate update.</p><p>The biopharmaceutical company reported a narrowed net loss of $3.71 per diluted share for 2025, an improvement from a loss of $7.83 per share in the prior year. This result also came in better than the $3.52 loss per share anticipated by analysts polled by FactSet.</p><p>Investor sentiment was further bolstered by several positive developments in the company's clinical pipeline. Palvella announced that the New Drug Application for its lead candidate, QTORIN™ rapamycin for microcystic lymphatic malformations, remains on track for submission in the second half of 2026. Additionally, the company plans to initiate a Phase 3 trial for cutaneous venous malformations in the latter half of 2026 and a Phase 2 trial for angiokeratomas in the second quarter of 2026. The corporate update also highlighted a recently completed $230 million equity financing that significantly strengthened the company's balance sheet.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Palvella Therapeutics Soars 6.18% Intraday on Narrowed Loss and Positive Clinical Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Palvella Therapeutics Soars 6.18% Intraday on Narrowed Loss and Positive Clinical Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-31 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Palvella Therapeutics' stock surged 6.18% during Tuesday's intraday trading session following the release of its full year 2025 financial results and a comprehensive corporate update.</p><p>The biopharmaceutical company reported a narrowed net loss of $3.71 per diluted share for 2025, an improvement from a loss of $7.83 per share in the prior year. This result also came in better than the $3.52 loss per share anticipated by analysts polled by FactSet.</p><p>Investor sentiment was further bolstered by several positive developments in the company's clinical pipeline. Palvella announced that the New Drug Application for its lead candidate, QTORIN™ rapamycin for microcystic lymphatic malformations, remains on track for submission in the second half of 2026. Additionally, the company plans to initiate a Phase 3 trial for cutaneous venous malformations in the latter half of 2026 and a Phase 2 trial for angiokeratomas in the second quarter of 2026. The corporate update also highlighted a recently completed $230 million equity financing that significantly strengthened the company's balance sheet.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PVLA","symbol_name":"Palvella Therapeutics","start_time":0,"source_url":"","article_id":"1128000407","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128000407","pubTimestamp":1774964128,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Palvella Therapeutics' stock surged 6.18% during Tuesday's intraday trading session following the release of its full year 2025 financial results and a comprehensive corporate update.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PVLA":"Palvella Therapeutics"},"translate_title":"个股追踪|Palvella Therapeutics盘中大涨6.18%，跌幅收窄，临床更新积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PVLA":1},"content_text":"Palvella Therapeutics' stock surged 6.18% during Tuesday's intraday trading session following the release of its full year 2025 financial results and a comprehensive corporate update.The biopharmaceutical company reported a narrowed net loss of $3.71 per diluted share for 2025, an improvement from a loss of $7.83 per share in the prior year. This result also came in better than the $3.52 loss per share anticipated by analysts polled by FactSet.Investor sentiment was further bolstered by several positive developments in the company's clinical pipeline. Palvella announced that the New Drug Application for its lead candidate, QTORIN™ rapamycin for microcystic lymphatic malformations, remains on track for submission in the second half of 2026. Additionally, the company plans to initiate a Phase 3 trial for cutaneous venous malformations in the latter half of 2026 and a Phase 2 trial for angiokeratomas in the second quarter of 2026. The corporate update also highlighted a recently completed $230 million equity financing that significantly strengthened the company's balance sheet.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}